cutaneous T cell lymphoma
Haematology · 2020–2020
1decision
1medicine
1carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| mogamulizumab Treatment of patients with relapsed or refractory cutaneous T cell lymphoma (CTCL) following at least one prior systemic treatment for the condition. | Jul 2020 | Not recommended | 1 individuals Leukaemia Foundation · Rare Cancers Australia |
Who spoke
Leukaemia Foundation · Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.